Washington Legal Foundation To Keep Eye On FDA’s Ad Division With “DDMAC Watch”
This article was originally published in The Pink Sheet Daily
Executive Summary
WLF will consider litigation against FDA in the case of inappropriate trends in the ad division’s warning and untitled letters. The program’s “rapid response” component will send responses to DDMAC letters specifically addressing “legally deficient or ill-advised” citations.
You may also be interested in...
WLF Could Return To Court Over FDA Drug Promotion Policies
Watchdog group’s citizen petition claims its yearlong study demonstrates FDA is in violation of First Amendment.
WLF Could Return To Court Over FDA Drug Promotion Policies
Watchdog group’s citizen petition claims its yearlong study demonstrates FDA is in violation of First Amendment.
VisionBlue Ad, Website Omit Risk Information, FDA Warning Letter Says
Dutch Ophthalmic has posted a disclaimer on its website and plans to run corrective ads in response to the citation for failing to include risk information in marketing materials for the staining agent. WLF's "DDMAC Watch" is challenging FDA's warning letter on VisionBlue.